QRQiurong Ruan

Qiurong Ruan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiurong Ruan has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Jianxin Song

    Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    11 shared publications
  • Jun Yu

    Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    11 shared publications
  • Jia Chen

    Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

    7 shared publications
  • Lili Yang

    Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China

    7 shared publications
  • Mincai Li

    7 shared publications
  • Wencong Zhang

    Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    7 shared publications

Latest Publications

  • Open Access

    HBsAg seroreversion after pegylated interferon alpha induced HBsAg seroclearance in patients with chronic hepatitis B: a real-world cohort study

    by Wencong Zhang, Jia Chen, Wenjin Sun, Nana Xie, Fangbing Tian, Wenyuan Zhang, Yan Wang, Qiurong Ruan, Jianxin Song

    The effect of different pegylated interferon alpha (Peg-IFNα) treatment strategies on the recurrence after Hepatitis B surface antigen (HBsAg) serocle

  • Open Access

    Clinical and Laboratory Discriminators for Tuberculosis and Lymphoma in Adults Presenting with Fever of Unknown Origin: A Prospective Cohort Study

    by Nana Xie, Fangbing Tian, Wencong Zhang, Jia Chen, Wenyuan Zhang, Qiurong Ruan, Jianxin Song

    Background: Tuberculosis and lymphoma are the common causes of fever of unknown origin (FUO) and show some similar clinical symptoms. The purpose of this study was to analyze the clinical characteristics of tuberculosis and lymphoma to find effective methods to distinguish them. Methods: A cohort including 100 tuberculosis and 81 lymphoma patients in FUO was prospectively enrolled. A predictive model of tuberculosis based on clinical parameters was established by using logistic regression equation, and its efficacy was evaluated by Receiving operating curve (ROC). Results: Both lymphoma and tuberculosis were more common in middle-aged and elderly males (P=0.043), and the total fever duration was relatively long (P=0.086). Muscle pain (P=0.017) and chills (P=0.045) were more common in tuberculosis patients, while hepatosplenomegaly (P< 0.001) and lymphadenopathy (P< 0.001) were more prevalent in lymphoma patients. The positive rate of T-SPOT.TB in the tuberculosis group was significantly higher than that in the lymphoma group (P< 0.001). In the lymphoma group, LDH and SF were all significantly increased (P< 0.001), while ALB and PLT were significantly decreased (P< 0.001). The AUC of the diagnostic prediction model for tuberculosis established by combining parameters was 0.96 (95% CI, 0.935– 0.986), with a sensitivity of 90.9% and a specificity of 87.1%. A validation cohort consisted of 42 patients with FUO from other departments during the same period, the AUC of the validation cohort was 0.948 (95% CI, 0.886– 0.999), with a sensitivity of 90% and a specificity of 90.9%. Conclusion: The integration of clinical parameters facilitates enhanced discriminative capacity between tuberculosis and lymphoma.

  • Open Access

    Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study

    by Wenyuan Zhang, Jia Chen, Wenjin Sun, Nana Xie, Fangbing Tian, Wencong Zhang, Qiurong Ruan, Jianxin Song

    Low-level viremia (LLV) is closely associated with the prognosis of patients with chronic hepatitis B (CHB), it can increase the incidence of cirrhosis and hepatocellular carcinoma. Our research aims to explore how to identify LLV early and implement effective therapeutic intervention. This retrospective study included 720 patients who were either treatment-naive or had not received treatment within the past 5 years. After 48 weeks follow-up, they were categorized into either the complete virological response (CVR) or LLV. Independent risk factors associated with LLV were screened by LASSO regression analysis and a prediction model incorporating these factors was developed. Furthermore, among patients who developed LLV, we compared the therapeutic efficacy of nucleos(t)ide analogue (NAs) monotherapy and pegylated interferon alpha (IFNα)-based combination therapy. Firstly, four independent risk variables were found to be connected to the incidence of LLV, including age, baseline HBV DNA level, baseline HBsAg level, and baseline HBeAg status. The model showed AUCs of 0.861 (training) and 0.799 (validation), with good calibration. Secondly, between IFNα-based combination therapy and NAs monotherapy group, HBV DNA clearance rates showed no difference at week 24 but significant divergence at week 48 (p = 0.684 and p = 0.001). HBsAg decline rates (in patients with baseline HBsAg ≥ 1500 IU/mL) differed significantly at both 24/48 weeks (p < 0.001). Throughout the 48-week follow-up, the cumulative rates of HBV DNA clearance (p < 0.001), HBsAg loss (p < 0.001), HBeAg loss (p = 0.008), and HBeAg seroconversion (p = 0.001) were all significantly higher in the combination therapy group, though the cumulative HBsAg seroconversion rate was not (p = 0.535). Furthermore, stratified analysis confirmed the superior efficacy of IFNα-based combination therapy across key subgroups. It outperformed NAs monotherapy both in patients with HBsAg ≥ 1500 IU/mL (24w: p = 0.031; 48w: p = 0.002) and in those with HBV DNA < 500 IU/mL (24w: p = 0.01; 48w: p < 0.001). Age, baseline HBV DNA level, HBsAg level, and HBeAg status were independently associated with the prevalence of LLV independently. Compared to NAs monotherapy, IFNα-based combination therapy in LLV patients demonstrated significantly higher rates of CVR, HBsAg decline, HBsAg loss/seroconversion, and HBeAg loss.


  • Open Access

    Clinical analysis of histiocytic necrotizing lymphadenitis in adults with fever of unknown origin: a retrospective study

    by Nana Xie, Wencong Zhang, Fangbing Tian, Jia Chen, Wenyuan Zhang, Qiurong Ruan, Jianxin Song

    To comprehensively analyze the clinical data of histiocytic necrotizing lymphadenitis (HNL) in adults with fever of unknown origin (FUO), with the aim of enabling precise diagnosis. A total of 15 HNL patients with FUO were enrolled. The analysis encompassed clinical manifestations, laboratory parameters 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) imaging profiles, pathological features and therapeutic responses. All patients presented with fever and lymphadenopathy (predominantly cervical). Laboratory findings included leukopenia (3.28 × 10⁹/L [2.40-4.97]), elevated LDH (306 U/L [187-524]), ESR (40 mm/h [30-51]), ferritin (457.1 ng/mL [206-1823.3]), and CRP (25 mg/L [6.1-34.8]) 18F-FDG PET/CT detected metabolic lymph node abnormalities in 13 cases, primarily cervical and axillary. The pathological features were extensive coagulative necrosis of lymph nodes with reactive hyperplasia of histiocytes as well as positive or scattered positivity IHC CD3, CD4, CD8 and CD68. Corticosteroid achieved favorable responses, with only 2 cases progressing during follow-up. In clinical practice, patients with fever and lymphadenopathy should be given due attention. Pathological examination remains the gold standard for diagnosing HNL. Glucocorticoid therapy has proven effective, and the majority of patients with HNL exhibit a favorable prognosis.


  • Fever of unknown origin: Clinical significance of the etiology and common inflammatory parameters

    by Nana Xie, Wencong Zhang, Fangbing Tian, Wenjin Sun, Mingyou Xing, Qiurong Ruan, Jianxin Song


  • Open Access

    Risk Factors of Hemophagocytic Lymphohistiocytosis in Adults with Fever of Unknown Origin: A Retrospective Study

    by Fangbing Tian, Nana Xie, Wenjin Sun, Wencong Zhang, Wenyuan Zhang, Jia Chen, Qiurong Ruan, Jianxin Song

    Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a critical syndrome with a high mortality rate. In clinical practice, some patients with fever of unknown origin (FUO) can develop HLH, further complicating the diagnosis and treatment. However, studies on HLH in adults with FUO are limited. This study aimed to investigate the clinical characteristics of adult patients with FUO to facilitate the early identification of those at high risk of developing HLH. Patients and Methods: We collected data from hospitalized patients with FUO between January 2014 and December 2020. Risk factors for HLH in adults with FUO were analyzed using univariate and multivariate analysis. Results: A total of 988 patients with FUO were included in the study. The incidence of HLH in adults with FUO was 6.4%, with hematological tumors being the primary cause. Multivariate analysis indicated that skin rash and elevated alanine aminotransferase, total bilirubin, triglycerides, lactate dehydrogenase, and ferritin levels were independent risk factors for HLH in adults with FUO. Conclusion: This study revealed the incidence rate, etiology distribution, and risk factors for HLH in adults with FUO. Comprehensive assessment of clinical and laboratory data at admission can assist in the early identification of FUO patients at risk for HLH.


  • Open Access

    The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment

    by Wencong Zhang, Jia Chen, Wenjin Sun, Nana Xie, Fangbing Tian, Qiurong Ruan, Jianxin Song

    Hepatitis B surface antigen (HBsAg) loss is regarded as a pivotal criterion for assessing functional cure in patients diagnosed chronic hepatitis B (CHB). We conducted the research to investigate the real-world performance of HBsAg seroconversion in sustaining HBsAg loss. This retrospective analysis confirmed 295 patients who attained HBsAg loss through combination therapy involving nucleos(t)ide analogues (NAs) and pegylated interferon alpha (peg-IFNα). Employing Kaplan–Meier estimates method to conduct survival analysis. The forest plot was used to visualize the results of multivariate Cox regression, and selected variables were included in the nomogram. HBsAg seroreversion was observed in 45 patients during follow-up periods, with a lower recurrence risk in patients with HBsAg seroconversion at the end of peg-IFNα therapy (EOT) (10.3% vs 37.3% at 96-week, P < 0.0001). Moreover, the sustainability of hepatitis B surface antibody (anti-HBs) in participants continuing therapy after HBsAg seroconversion was superior to those discontinued prematurely (72.5% vs 54.5% at 96 weeks, P = 0.012). Additionally, the former group was also relatively less likely to experience HBsAg reversion during long-term observation (8.4% vs 14.3% at 96 weeks, P = 0.280). Hepatitis B envelope antigen (HBeAg) status, anti-HBs status and consolidation treatment screened by multivariable analysis were utilized to construct a predictive model for HBsAg reversion. The concordance index(C-index = 0.77) and calibration plots indicated satisfactory discrimination and consistency of nomogram. HBsAg seroconversion was beneficial for sustaining functional cure in patients treated with peg-IFNα. Continuing consolidation therapy after HBsAg seroconversion also contributed to maintain HBsAg seroconversion and improve the durability of HBsAg loss. The nomogram illustrated its efficacy as a valuable instrument in showcasing survival probability of functional cure.


  • Open Access

    Differential diagnosis of lymphoma with 18F-FDG PET/CT in patients with fever of unknown origin accompanied by lymphadenopathy

    by Jia Chen, Dong Xu, Wen-Jin Sun, Wen-Xia Wang, Na-Na Xie, Qiu-Rong Ruan, Jian-Xin Song

    Purpose: To investigate the value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of lymphoma in patients with fever of unknown origin (FUO) accompanied by lymphadenopathy and to develop a simple scoring system to distinguish lymphoma from other etiologies. Methods: A prospective study was conducted on patients with classic FUO accompanied by lymphadenopathy. After standard diagnostic procedures, including PET/CT scan and lymph-node biopsy, 163 patients were enrolled and divided into lymphoma and benign groups according to the etiology. The diagnostic utility of PET/CT imaging was evaluated, and beneficial parameters that could improve diagnostic effectiveness were identified. Results: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PET/CT in diagnosing lymphoma in patients with FUO accompanied by lymphadenopathy were 81.0, 47.6, 59.3, and 72.7%, respectively. The lymphoma prediction model combining high SUVmax of the “hottest” lesion, high SUVmax of the retroperitoneal lymph nodes, old age, low platelet count, and low ESR had an area under the curve of 0.93 (0.89–0.97), a sensitivity of 84.8%, a specificity of 92.9%, a PPV of 91.8%, and an NPV of 86.7%. There was a lower probability of lymphoma for patients with a score < 4 points. Conclusions: PET/CT scans show moderate sensitivity and low specificity in diagnosing lymphoma in patients with FUO accompanied by lymphadenopathy. The scoring system based on PET/CT and clinical parameters performs well in differentiating lymphoma and benign causes and can be used as a reliable noninvasive tool. Registration number: This study on FUO was registered on http://www.clinicaltrials.gov on January 14, 2014, with registration number NCT02035670.


  • Open Access

    Diagnostic models for fever of unknown origin based on 18F-FDG PET/CT: a prospective study in China

    by Jia Chen, MingYou Xing, Dong Xu, NaNa Xie, WenCong Zhang, QiuRong Ruan, JianXin Song

    Background: This study aims to analyze the 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) characteristics of different causes of fever of unknown origin (FUO) and identify independent predictors to develop a suitable diagnostic model for distinguishing between these causes. A total of 524 patients with classical FUO who underwent standard diagnostic procedures and PET/CT were prospectively studied. The diagnostic performance of PET/CT imaging was analyzed, and relevant clinical parameters that could improve diagnostic efficacy were identified. The model was established using the data of 369 patients and the other 155 patients comprised the validation cohort for verifying the diagnostic performance of the model. Results: The metabolic characteristics of the “hottest” lesion, the spleen, bone marrow, and lymph nodes varied for various causes. PET/CT combined with clinical parameters achieved better discrimination in the differential diagnosis of FUO. The etiological diagnostic models included the following factors: multisite metabolic characteristics, blood cell counts, inflammatory indicators (erythrocyte sedimentation rate, C-reactive protein, serum ferritin, and lactate dehydrogenase), immunological indicators (interferon gamma release assay, antinuclear antibody, and anti-neutrophil cytoplasm antibody), specific signs (weight loss, rash, and splenomegaly), and age. In the testing cohort, the AUCs of the infection prediction model, the malignancy diagnostic model, and the noninfectious inflammatory disease prediction model were 0.89 (95% CI 0.86–0.92), 0.94 (95% CI 0.92–0.97), and 0.95 (95% CI 0.93–0.97), respectively. The corresponding AUCs for the validation cohort were 0.88 (95% CI 0.82–0.93), 0.93 (95% CI 0.89–0.98), and 0.95 (95% CI 0.92–0.99), respectively. Conclusions: 18F-FDG PET/CT has a certain level of sensitivity and accuracy in diagnosing FUO, which can be further improved by combining it with clinical parameters. Diagnostic models based on PET/CT show excellent performance and can be used as reliable tools to discriminate the cause of FUO. Trial registration This study (a two-step method apparently improved the physicians’ level of diagnosis decision-making for adult patients with FUO) was registered on the website http://www.clinical-trials.gov on January 14, 2014, with registration number NCT02035670.


  • Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19

    by Kun Yang, Ming-You Xing, Ling-Yu Jiang, Yan-Ping Cai, Li-Li Yang, Na-Na Xie, Jia Chen, Wen-Xia Wang, Li Wang, Ji-Ling Zhu, et al.

    Summary Infection-associated hemophagocytic syndrome (IAHS), a severe complication of various infections, is potentially fatal. This study aims to determine whether IAHS occurs in critically ill patients with coronavirus disease 2019 (COVID-19). We conducted a retrospective observational study on 268 critically ill patients with COVID-19 between February 1st, 2020 and February 26th, 2020. Demographics, clinical characteristics, laboratory results, information on concurrent treatments and outcomes were collected. A diagnosis of secondary hemophagocytic lymphohistiocytosis (sHLH) was made when the patients had an HScore greater than 169. Histopathological examinations were performed to confirm the presence of hemophagocytosis. Of 268 critically ill patients with confirmed SARS-CoV-2 infection, 17 (6.3%) patients had an HScore greater than 169. All the 17 patients with sHLH died. The interval from the onset of symptom of COVID-19 to the time of a diagnosis of sHLH made was 19 days and the interval from the diagnosis of sHLH to death was 4 days. Ten (59%) patients were infected with only SARS-CoV-2. Hemophagocytosis in the spleen and the liver, as well as lymphocyte infiltration in the liver on histopathological examinations, was found in 3 sHLH autopsy patients. Mortality in sHLH patients with COVID-19 is high. And SARS-CoV-2 is a potential trigger for sHLH. Prompt recognition of IAHS in critically ill patients with COVID-19 could be beneficial for improving clinical outcomes.